Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

Medtronic is racing against Boston Scientific to expand in one of medtech’s hottest markets, pulsed field ablation (PFA). The new technology treats atrial fibrillation, an abnormal heartbeat ...

That leaves Medtronic, which recently called cardiac ablation a $9 billion segment, as Boston Scientific’s current rival in PFA. Boston Scientific reported a 177% increase in global ...

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, ...

Medtronic remains a "Buy" due to its undervalued ... Notably, supply chain challenges for the pulse field ablation product impeded Cardiovascular expansion for a while, however, these issues ...

Pulsed-field ablation catheters can come in a variety of shapes and sizes. The catheters shown here are for (from top to bottom) Boston Scientific’s Farapulse, Medtronic’s Affera, Medtronic ...

Let's take a closer look at whether Medtronic's dividend is safe and if you can comfortably rely on its payout for the foreseeable future. Medtronic's payout ratio is well over 80% A stock's ...